WVU Medicine is playing a lead role in a national clinical study of a minimally invasive surgical procedure for people who've ...

Novo Nordisk shares dropped due to CagriSema trial results but have long-term upside. Learn why NVO stock is a Strong Buy ...

Compounded semaglutide is legal, but it's not regulated in the same way as medications like Ozempic and Wegovy.

Eli Lilly and Company’s LLY shares have risen 4.3% since it reported fourth-quarter results on Feb. 6. Lilly’s fourth-quarter ...

"They’re priced for profits, not patients.” That’s the critique from Hims & Hers Health’s buzzy — and controversial — Super ...

Two healthcare stocks that may or may not be boring, but that regardless look like strong growth stocks to invest in this ...

Its lineup features several blockbusters, including its popular diabetes and weight loss medicines, Mounjaro and Zepbound ... was able to hear for the first time. Eli Lilly's late-stage pipeline ...

Independence Blue Cross began limiting coverage of GLP-1 drugs on Jan. 1 to some medical conditions, but not obesity or weight loss.

Beyond treating diabetes and helping people lose weight, GLP-1s may also improve libido. But the reasons are as complex as ...

Among those who adhered to treatment, the high-dose group achieved an average weight loss ... Zepbound (tirzepatide), which helped patients shed 20.9% of their weight at the same 72-week time ...

The US Food and Drug Administration (FDA) has declared an end to the shortage of tirzepatide, the active ingredient in Eli Lilly’s popular weight loss medication Zepbound and diabetes drug Mounjaro.

But faced with a $1,200 monthly price tag for her weight loss medication ... and potential jail time. These arrests can have lasting impacts on employment opportunities and professional licenses ...